122341-40-6
122341-40-6 結(jié)構(gòu)式
基本信息
Neuropeptide Y(13-36)【rat】
13-36-Human neuropeptide Y
NEUROPEPTIDE Y (13-36) HUMAN
PAEDMARYYSALRHYINLITRQRY-NH2
NEUROPEPTIDE Y (13-36), HUMAN, RAT
13-36-Neuropeptide Y (human) (9CI)
Neuropeptide Y (13-36), amide, human
PRO-ALA-GLU-ASP-MET-ALA-ARG-TYR-TYR-SER-ALA-LEU-ARG-HIS-TYR-ILE-ASN-LEU-ILE-THR-ARG-GLN-ARG-TYR-NH2
H-PRO-ALA-GLU-ASP-MET-ALA-ARG-TYR-TYR-SER-ALA-LEU-ARG-HIS-TYR-ILE-ASN-LEU-ILE-THR-ARG-GLN-ARG-TYR-NH2
物理化學(xué)性質(zhì)
常見問題列表
|
NPYY 2 receptor
|
Neuropeptide Y (13-36) (intraventricular injection; 25-3000 pmol) produces a dose-dependent increase (up to 14%; ED 50 value of 0.3 nmol for overall effects and 0.97 nmol for the peak effects) in mean arterial blood pressure in the awake, unrestrained male rat without affecting heart rate. Central administration of porcine Neuropeptide Y (13-36) produces marked vasodepressor and bradycardic actions in the anaesthetized α-chloralose and in the awake unrestrained male rat.Neuropeptide Y (13-36) (intracerebroventricular injection; 50 ng; alone; injected 30 and 15 min before measurements) injected into na?ve mice impairs social novelty preference, but not sociability, and this effect is inhibited by the NPY Y 2 receptor antagonist BIIE 0246.
| Animal Model: | Male ICR mice (age 4-7 weeks) |
| Dosage: | 50 ng/mouse |
| Administration: | Intracerebroventricular injection |
| Result: | Significantly decreased interaction time with the new stranger mouse in session 3 that NPY 13-36. |